Del Rosso James Q, Harper Julie, Kircik Leon, Albon Glynis, Berson Diane, Hebert Adelaide, Day Doris
J Drugs Dermatol. 2018 Oct 1;17(10):1070-1076.
Atopic dermatitis (AD) is well-recognized as a very common chronic and relapsing pruritic skin disorder affecting both children and adults worldwide. The adverse effects on the quality of life of affected individuals and their families is well-established. The pathophysiology of AD is complex, leading to interindividual variations in clinical presentation and severity. The chronicity of AD, characterized by periods of exacerbation and remission, supports a strong need to develop measures that can effectively and safely prolong remissions between flares of the disease. This article provides an overview of AD including prevalence, severity, and disease course/progression, succinct summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with AD. Additional emphasis is placed on adjunctive topical skin barrier approaches that may prolong disease-free remissions. Results from a panel of dermatologists queried about adjunctive approaches to AD, using a modified-Delphi approach, are also discussed. J Drugs Dermatol. 2018;17(10):1070-1076.
THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE.
PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN.
NO PURCHASE NECESSARY.
PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
.特应性皮炎（AD）是一种公认的非常常见的慢性复发性瘙痒性皮肤病，影响着全球的儿童和成人。其对患者及其家庭生活质量的不良影响已得到充分证实。AD的病理生理学很复杂，导致临床表现和严重程度存在个体差异。AD的慢性特征表现为病情加重和缓解期交替，这强烈表明需要开发能够有效且安全地延长疾病发作间期缓解期的措施。本文概述了AD，包括患病率、严重程度和疾病进程/进展，简要总结了病理生理学和药物治疗，并讨论了与AD相关的表皮屏障功能障碍和皮肤微生物群变化。还特别强调了可能延长无病缓解期的辅助性局部皮肤屏障方法。此外，还讨论了一组皮肤科医生采用改良德尔菲法对AD辅助治疗方法进行调查的结果。《皮肤药物学杂志》。2018年；17（10）：1070 - 1076。
本文已免费提供。
请向下滚动以在无需登录的情况下访问本文全文。
无需购买。
如有任何疑问，请联系出版商。
